Liminatus Pharma Inc [NASDAQ: LIMN] gained 22.66% or 0.63 points to close at $3.41 with a heavy trading volume of 35465625 shares.
It opened the trading session at $3.83, the shares rose to $4.06 and dropped to $3.09, the range by which the price of stock traded the whole day. The daily chart for LIMN points out that the company has recorded -69.08% loss over the past six months.
If we look at the average trading volume of 656.22K shares, LIMN reached to a volume of 35465625 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Trading performance analysis for LIMN stock
Liminatus Pharma Inc [LIMN] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -14.75. With this latest performance, LIMN shares dropped by -59.74% in over the last four-week period, additionally sinking by -69.08% over the last 6 months – not to mention a drop of -69.61% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for LIMN stock in for the last two-week period is set at 37.33, with the RSI for the last a single of trading hit 0.77, and the three-weeks RSI is set at 1.38 for Liminatus Pharma Inc [LIMN]. The present Moving Average for the last 50 days of trading for this stock 8.30, while it was recorded at 3.47 for the last single week of trading.
Liminatus Pharma Inc (LIMN) Capital Structure & Debt Analysis
Liminatus Pharma Inc (LIMN) Efficiency & Liquidity Metrics
Liminatus Pharma Inc (LIMN) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Liminatus Pharma Inc. (LIMN) effectively leverages its workforce, generating an average of -$683333.33 per employee. The company’s liquidity position is robust, with a Current Ratio of 0.00% and a Quick Ratio of 0.00%, indicating strong ability to cover short-term liabilities.
An analysis of Institutional ownership at Liminatus Pharma Inc [LIMN]
There are presently around $0.76%, or 3.68%% of LIMN stock, in the hands of institutional investors.
